Consensus Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.64 ^USD	+0.87%		+2.92%	+43.17%

Mar. 29	General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	CI
Mar. 14	Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	MT

Evolution of the average Target Price on Iovance Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

df80a4d6cc90eb77b07e6348.105irRJW0lNub6Q_f3023IJlOYb3dq5hJGl1KOF32zA.-hgx2VN7uhQJXOJqG1Bgqc8rFN-lNMMEXD4yX9cCtweZPw7CfmOXIRsO9Q~1b87eb047d2ab07bae1a1089129a67c5

Analyst Recommendations on Iovance Biotherapeutics, Inc.

Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	Mar. 14	MT
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating	Mar. 01	MT
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating	Feb. 29	MT
Goldman Sachs Raises Price Target on Iovance Biotherapeutics to $19 From $13, Maintains Buy Rating	Feb. 20	MT
Piper Sandler Adjusts Price Target on Iovance Biotherapeutics to $18 From $14, Maintains Overweight Rating	Feb. 20	MT
Dwindling Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Feb. 20	MT
Chardan Boosts Price Target on Iovance Biotherapeutics to $34 From $29, Keeps Buy Rating	Feb. 20	MT
HC Wainwright Cuts Price Target on Iovance Biotherapeutics to $28 From $38, Maintains Buy Rating	Nov. 08	MT
Barclays Cuts Price Target on Iovance Biotherapeutics to $18 From $40, Maintains Overweight Rating	23-09-18	MT
Stifel Nicolaus Adjusts Iovance Biotherapeutics Price Target to $25 From $27, Maintains Buy Rating	23-09-13	MT
Wells Fargo Upgrades Iovance Biotherapeutics to Overweight From Equalweight, Raises Price Target to $17 From $11	23-05-30	MT
Stifel Adjusts Price Target on Iovance Biotherapeutics to $24 From $21, Maintains Buy Rating	23-05-30	MT
Baird Adjusts Iovance Biotherapeutics Price Target to $23 From $20, Maintains Outperform Rating	23-05-23	MT
Baird Adjusts Price Target on Iovance Biotherapeutics to $20 From $25, Maintains Outperform Rating	23-05-10	MT
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $11 From $14, Maintains Equal-Weight Rating	23-03-06	MT
Oppenheimer Adjusts Iovance Biotherapeutics' Price Target to $15 From $25, Maintains Outperform Rating	23-03-01	MT
Piper Sandler Upgrades Iovance Biotherapeutics to Overweight From Neutral, Adjusts Price Target to $14 From $11	23-01-27	MT
Truist Securities Adjusts Iovance Biotherapeutics' Price Target to $17 From $16, Keeps Buy Rating	23-01-24	MT
Goldman Sachs Downgrades Iovance Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20	22-12-09	MT
JMP Securities Lowers Price Target on Iovance Biotherapeutics to $21 From $25, Maintains Market Outperform Rating	22-11-21	MT
Piper Sandler Adjusts Iovance Biotherapeutics' Price Target to $11 From $13, Keeps Neutral Rating	22-11-21	MT
Chardan Trims Price Target on Iovance Biotherapeutics to $29 From $30, Lowers Sales Projections; Maintains Buy Rating	22-11-21	MT
Iovance Biotherapeutics Says Study of Advanced Melanoma Treatment Shows 'Meaningful' Response Rate, Shares Rise 9%	22-11-10	MT
Guggenheim Initiates Iovance Biotherapeutics at Neutral	22-10-31	MT
Truist Securities Lowers Iovance Biotherapeutics' Price Target to $18 From $20, Maintains Buy Rating	22-08-23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.64 USD

Average target price

26 USD

Spread / Average Target

+123.37%

High Price Target

34 USD

Spread / Highest target

+192.10%

Low Price Target

19 USD

Spread / Lowest Target

+63.23%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Iovance Biotherapeutics, Inc.

Piper Sandler
Wells Fargo Securities
Barclays
Goldman Sachs
Chardan Research
HC Wainwright
Stifel Nicolaus
Baird
Oppenheimer
Truist Securities
JMP Securities
Guggenheim
Chardan
Jefferies & Co.

Ratings for Iovance Biotherapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar